Artiva Biotherapeutics (ARTV) News Today $12.78 +0.18 (+1.43%) (As of 11/29/2024 05:27 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Acuta Capital Partners LLC Takes $680,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Acuta Capital Partners LLC purchased a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 44,000 shares of the company'sNovember 28 at 8:12 AM | marketbeat.comComparing Neurocrine Biosciences (NASDAQ:NBIX) & Artiva Biotherapeutics (NASDAQ:ARTV)November 23, 2024 | americanbankingnews.comCantor Fitzgerald Forecasts ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer expects thaNovember 18, 2024 | marketbeat.comWedbush Has Bearish Forecast for ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush cut their FY2024 earnings per share estimates for Artiva Biotherapeutics in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per shareNovember 15, 2024 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Announces Earnings ResultsArtiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24).November 14, 2024 | marketbeat.comArtiva Biotherapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | tipranks.comArtiva Biotherapeutics, Inc.: Strong Buy Rating Supported by Robust Autoimmune Pipeline and Financial StabilityNovember 13, 2024 | markets.businessinsider.comNeedham & Company LLC Reiterates "Buy" Rating for Artiva Biotherapeutics (NASDAQ:ARTV)Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday.November 13, 2024 | marketbeat.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 12, 2024 | globenewswire.comArtiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 11, 2024 | globenewswire.comArtiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsOctober 22, 2024 | globenewswire.comArtiva Biotherapeutics (NASDAQ:ARTV) Shares Down 5.4% - Time to Sell?Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4% - Time to Sell?October 15, 2024 | marketbeat.comArtiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comBuy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial OptimismSeptember 4, 2024 | markets.businessinsider.comArtiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by WedbushWedbush reaffirmed an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday.August 31, 2024 | marketbeat.comBuy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong FinancialsAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from WedbushAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 30, 2024 | finanznachrichten.deArtiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 30, 2024 | markets.businessinsider.comThis Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative TreatmentAugust 29, 2024 | fool.comArtiva Biotherapeutics, Inc.'s (NASDAQ:ARTV) Quiet Period Will End on August 28thArtiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) quiet period is set to expire on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During Artiva Biotherapeutics' quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.August 21, 2024 | marketbeat.comArtiva Biotherapeutics shares get Overweight ratingAugust 15, 2024 | uk.investing.comAnalysts Set Expectations for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV)Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at Wedbush issued their Q2 2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten expects that the company will earn ($1.5August 15, 2024 | marketbeat.comArtiva Biotherapeutics, Inc. (ARTV)August 13, 2024 | finance.yahoo.comBuy Rating Affirmed: Artiva Biotherapeutics’ Promising AlloNK Cell Therapy in the Autoimmune SpaceAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Artiva Biotherapeutics Amid Promising NK Cell Therapy DevelopmentsAugust 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish PitchAugust 13, 2024 | benzinga.comJefferies Financial Group Begins Coverage on Artiva Biotherapeutics (NASDAQ:ARTV)Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research report on Tuesday. They set a "buy" rating and a $21.00 price target for the company.August 13, 2024 | marketbeat.comArtiva Biotherapeutics Inc ARTVJuly 31, 2024 | morningstar.comInsider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up SharesJuly 28, 2024 | 247wallst.comArtiva Biotherapeutics Inc (ARTV)July 23, 2024 | investing.comInsider Buying: Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Buys 416,666 Shares of StockJuly 23, 2024 | insidertrades.com Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crisis Could Be Worse Than 2008 (Ad)Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen. In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street. ARTV Media Mentions By Week ARTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTV News Sentiment▼1.320.87▲Average Medical News Sentiment ARTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTV Articles This Week▼31▲ARTV Articles Average Week Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VIR News REPL News LENZ News IMTX News RLAY News ADPT News AUTL News AVXL News CRGX News CGEM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTV) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
